JAK2 and Thrombocytosis: Individuals with thrombocytosis, compared with their matched controls, had a higher prevalence of JAK2 (12.8% vs 1.1%; P < 0.001) (all V617F mutations) and CALR mutations (4.7% vs 0.0%; P = 0.003; Figure 3B).